Summary Immunohistochemical assays have been employed to study the expression of ER, PgR, EGFR and Ki67 immunostaining in normal breast tissue (n = 76). The expression of ER and PgR was highly variable in both pre and postmenopausal women and was characterised by large numbers of apparently negative cells. This was most evident for ER-ICA staining in tissues removed from premenopausal women. PgR levels were highest in the ducts of premenopausal women, while EGFR expression was elevated in both ducts and lobules. Ki67 expression was observed in < 10% of all normal cells and was suppressed by the menopause in lobular tissue. (Fentiman, 1989; Powles et al., 1989) . The concept is largely based on the epidemiological observations that an early age of natural menopause or early oophorectomy for reasons other than breast cancer, substantially reduces the incidence of the disease (Pike et al., 1989) . Currently tamoxifen is the most likely candidate for such a prophylactic regime, since the antioestrogen has not only proven effectiveness in both primary (SBCT report, 1987; Nato report, 1990) and advanced (Patterson et al., 1981; Furr & Jordan, 1984) breast cancer, but also shows a low incidence of side-effects. Moreover, in primary breast cancer patients treated with tamoxifen as an adjuvant to surgery it has now been observed that there is a reduction in the development of contralateral breast cancer, suggesting that the drug is indeed preventing the development of the disease (Nato report, 1990). Unfortunately, one of the major concerns about tamoxifen is that little is known of its effects on normal breast tissue. This is of particular concern since animal experiments have demonstrated that tamoxifen can show oestrogen-like properties (Furr & Jordan, 1984) and is capable of promoting full ductal development in the rat mammary gland (Nicholson et al., 1988 Ki67 immunostaining was performed using methods previously described (Bouzubar et al., 1989) . The immunohistochemical detection of EGFR was undertaken using a previously unpublished procedure. Briefly, cryostat sections (5 Lm) were mounted on slides coated with a tissue adhesive and air dried for at least 2 h and stored at -70'C prior to assay. Sections were fixed in acetone/chloroform (1:1) at 4'C for 10 min then washed in Tris buffered saline (10 mM Tris, pH 7.4; TBS) before incubation with a normal goat serum (diluted 1:10 with TBS) for 10 min. Excess serum was removed and the slides were incubated for a further 60 min with the primary antibody (1 Lg ml final concentration, Amersham, UK) in 10% normal goat serum and 5% normal human serum in TBS). The slides were washed three times in TBS and reincubated for 30 min with rabbit anti-mouse peroxidase conjugate (diluted 1:50 in 10% normal goat serum and 5% normal human serum in TBS) followed by 2 washes in TBS. Sections were immersed for 6 min in a chromogen substrate bath containing DAB (150 mg) and imidazole (150 mg) in 300 ml TBS, to which had been added 99 il of 30% (w/v) hydrogen peroxide. The reaction was stopped by washing the sections for 1 min in distilled water followed by a further 1 min exposure to 0.5% CuSO4 in 0.85% NaOH which enhances the end product colouration. The sections were counterstained with methyl green (1% aqueous) for 6 min. The slides were then rinsed in tap water for 5 min, dehydrated in serially graded alcohols, cleared in
A number of recent publications have suggested that breast cancer might be prevented by the antihormonal treatment of women who are deemed to be at high risk of developing the malignancy (Fentiman, 1989; Powles et al., 1989) . The concept is largely based on the epidemiological observations that an early age of natural menopause or early oophorectomy for reasons other than breast cancer, substantially reduces the incidence of the disease (Pike et al., 1989) . Currently tamoxifen is the most likely candidate for such a prophylactic regime, since the antioestrogen has not only proven effectiveness in both primary (SBCT report, 1987; Nato report, 1990 ) and advanced (Patterson et al., 1981; Furr & Jordan, 1984) breast cancer, but also shows a low incidence of side-effects. Moreover, in primary breast cancer patients treated with tamoxifen as an adjuvant to surgery it has now been observed that there is a reduction in the development of contralateral breast cancer, suggesting that the drug is indeed preventing the development of the disease (Nato report, 1990) . Unfortunately, one of the major concerns about tamoxifen is that little is known of its effects on normal breast tissue. This is of particular concern since animal experiments have demonstrated that tamoxifen can show oestrogen-like properties (Furr & Jordan, 1984) and is capable of promoting full ductal development in the rat mammary gland (Nicholson et al., 1988 (Gerdes et al., 1984) and thus enables an estimate of the tissue growth fraction (Gerdes et al., 1984; Gerdes et al., 1986) . In breast tumours a significant correlation has been recorded between Ki67 immunostaining and the mitotic activity of breast cancer (Gerdes et al., 1986; Bouzubar et al., 1989) and with early recurrence of the disease after mastectomy (Bouzubar et al., 1989 Ki67 immunostaining was performed using methods previously described (Bouzubar et al., 1989) . The immunohistochemical detection of EGFR was undertaken using a previously unpublished procedure. Briefly, cryostat sections (5 Lm) were mounted on slides coated with a tissue adhesive and air dried for at least 2 h and stored at -70'C prior to assay. Sections were fixed in acetone/chloroform (1:1) at 4'C for 10 min then washed in Tris buffered saline (10 mM Tris, pH 7.4; TBS) before incubation with a normal goat serum (diluted 1:10 with TBS) for 10 min. Excess serum was removed and the slides were incubated for a further 60 min with the primary antibody (1 Lg ml final concentration, Amersham, UK) in 10% normal goat serum and 5% normal human serum in TBS). The slides were washed three times in TBS and reincubated for 30 min with rabbit anti-mouse peroxidase conjugate (diluted 1:50 in 10% normal goat serum and 5% normal human serum in TBS) followed by 2 washes in TBS. Sections were immersed for 6 min in a chromogen substrate bath containing DAB (150 mg) and imidazole (150 mg) in 300 ml TBS, to which had been added 99 il of 30% (w/v) hydrogen peroxide. The reaction was stopped by washing the sections for 1 min in distilled water followed by a further 1 min exposure to 0.5% CuSO4 in 0.85% NaOH which enhances the end product colouration. The sections were counterstained with methyl green (1% aqueous) for 6 min. The slides were then rinsed in tap water for 5 min, dehydrated in serially graded alcohols, cleared in xylene and mounted under coverslips in dibutylpthalate xylene solution. Control slides in which the primary antibody had been replaced with an equivalent concentration of mouse anti-sheep erythrocytes were included in each assay, enabling assessment of non-specific binding. A highly EGFR positive tumour was also incorporated into each assay as a positive control.
Specimen evaluation All specimen evaluation was performed on an Olympus microscope (BH-2) using an occular magnification of x 40. Control slides were checked for non-specific binding before assessing the percentage of cells stained by the primary antibodies. Quantitative assessments were made for each antigen of the number of positive and negative stained cells in 20 samples. For each tissue a total of 10 fields were counted and a mean percentage staining figure was calculated. After a lapse of 2 weeks the same samples and fields were re-evaluated by two personnel using a dual viewing attachment to the Olympus microscope estimating the numbers of positive and negative cells. Comparison of the results obtained using both methods of assessment demonstrated excellent agreement (r=0.82, P<0.01). The latter method was therefore used throughout the study.
Results

Untreated breast tissue
In normal breast tissue from control patients, the immunohistochemical localisation of ER using the antihuman ER rat monoclonal antibody H222 showed specific binding in the nuclei of epithelial cells with no binding being observed in the cytoplasm or stromal components. Considerable heterogeneity of ER expression was, however, evident in both ductal (Plate la) and lobular (Plate lb) structures. Examination of the distribution of ER positivity in lobules indicated a trend for an increase in the proportion of ER positive cells in postmenopausal women (Figure la ; P = 0.02). Values for ER positivity in ductal tissue were lower than those obtained in lobular specimens and were similar in both pre-and postmenopausal women (Figure lb) .
The distribution of the progesterone receptor in normal breast tissue was similar to that observed for ER with the majority of parenchymal structures showing variable numbers of positive cells (Plate lc,d). Unlike ER, however, PgR expression was highest in premenopausal women with this achieving significance (P = 0.04) in the ductal components (Figure lc,d) . Examination of EGFR in normal tissue showed a consistently high expression of cell membrane staining in both ducts and lobules (Plate le,f). The staining was most evident towards the basement membrane, with luminal epithelial cells occasionally being recorded as negative. No obvious differences were observed in EGFR levels between pre and postmenopausal women and between ducts and lobules (not illustrated). Due to the high proportion of positive EGFR cells and their distribution in normal structures it was not possible to quantify EGFR measurements.
Ki67 binding in all normal breast tissues examined was much lower than that recorded with the other antibodies with characteristically < 10% cells immunostaining (Plate lg,h, Figure le,f) . Indeed in 25% of the samples no Ki67 immunostaining was recorded. Highest levels of Ki67 positivity were observed in the lobules removed from premenopausal women (P = 0.02). 
Discussion
The antioestrogen tamoxifen has been suggested as a suitable prophylactic agent for the prevention of breast cancer in women who are deemed to be at high risk of developing the disease. This is in spite of very little information being available concerning the actions of the antioestrogen on the parenchymal structures of the normal breast. In our current study we have been able to establish using a number of immunohistochemical markers of hormone and growth factor receptors and a cell proliferation marker, that although tamoxifen may upregulate ER expression in ductal structures removed from postmenopausal treated patients, it shows no stimulatory activity on either PgR levels, a well known oestrogen regulated protein (Katzenellenbogen et al., 1987; Welshons et al., 1987) or the important parameter of cell proliferation (Figure 2 ). This is despite each of these end points showing a degree of hormonal regulation in nontreated patients, with their levels being modified by menopausal status (Figure 1) .
Since Ki67 immunostaining occurs at low frequency in the breast tissue of postmenopausal women (< 5% cell staining) we envisaged that any stimulatory activity of tamoxifen on cell proliferation should have been readily detected. The absence of any increases in the proportion of Ki67 positive cells in any of the samples removed from women after both short (2 days to 1 month) and long (> 2 months) term tamoxifen treatment (Figure 3 ) suggests no adverse actions of the drug on normal breast tissue. Although our current study was largely performed on postmenopausal women, two samples removed from tamoxifen-treated premenopausal women also showed no evidence of elevated rates of cell proliferation. The ER and PgR values recorded in these specimens, however, were above the median values for the group in both ducts and lobules.
The data recorded above is in contrast to the oestrogenlike activity of tamoxifen on the human pituitary gland, uterus and liver of postmenopausal women, where the drug reduces elevated gonadotrophin levels (Furr & Jordan, 1984) , increases the karyopyknotic index of the uterus (Ferrazzi et al., 1977) and increases the serum concentrations of several oestrogen-regulated liver proteins (Sakai et al., 1978; Boccardo et al., 1981; Fex et al., 1981) . These results reflect the complex pharmacology of tamoxifen which is species, tissue and cell type specific (Furr & Jordan, 1984) and whose properties can range from a full oestrogen with no antagonistic properties towards oestradiol, to a full antagonist with no oestrogenicity. Indeed, we have previously ascribed the former property to tamoxifen with regards to its action on the rat mammary gland where it is a full agonist on ductal development and stimulates a large proliferative response in the terminal end buds, the main growth regions of the gland (Nicholson et al., 1988) . These studies were, however, carried out on pubertal animals during the active growth phase of mammary gland development. In mature cycling animals tamoxifen acts as an antioestrogen causing atrophy of lobular structures (Gotz et al., 1984) . In this light it may be significant that tamoxifen treatment of postmenopausal women resulted in some upregulation of the proportion of ductal epithelial cells expressing ER. Since, a similar phenomenon occurs in the transition between pre-and postmenopausal women, in both the normal (Figure 1) (Sainsbury et al., 1985) , where EGFR immunostaining is associated with high grades of tumour malignancy (Lewis et al., 1990) . Moreover, in breast cancer specimens Ki67 immunostaining also correlates with EGFR expression (McClelland & Nicholson, in preparation) and poor prognosis (Sainsbury et al., 1987) . These differences may result from the low availability of the ligands for the EGFR in normal tissues (Elder et al., 1975; Kaselberg et al., 1985; Poulsen et al., 1986) and the presence of readily detectable amounts of TGF-a, the tumour homologue of EGF in the majority of breast cancers (Macias et al., 1989 
